Notifying us about adverse reactions to cannabis and cannabis products is crucial for obtaining necessary information regarding the potential dangers and benefits of cannabis. If you are reporting adverse reactions, please include as much information as possible, including the name of your licensed producer, the product brand, the strain name, and any other information that may be useful in reporting adverse reactions. Health Canada can help with any follow-ups or actions by providing as much detail as possible regarding the negative response.
These bullet-point statements summarise the content within sections 4.0 and 7.0 (Potential Therapeutic uses) and their respective subsections. You can find the bullet-point messages in the individual sections and subsections within the body of this GTS-21 document. Most clinical studies of cannabis (experimental and therapeutic) were conducted using dried cannabis that contains more THC than CBD. The THC content is typically lower ( 9% THC), but this has not been the norm. Most clinical studies of cannabis (experimental and therapeutic) used dried cannabis. The results of clinical studies on cannabis for medicinal purposes could not be applied to other chemotypes or cannabis products with different THC/CBD amounts.
For completeness and context purposes, the following document includes information regarding dried cannabis and other cannabis products. Even though the data is provided on cannabis products and cannabinoids, they should not be considered equivalent. While cannabis and cannabis products have hundreds of chemical constituents, cannabinoids typically only contain single molecules. When comparing cannabis products with cannabinoids, it is important to consider differences in how they are administered, their dosage, their pharmacological components, their interactions, and the different pharmacokinetics and pharmacodynamic properties.
As for Ondansetron. Diarrhea, stomach pain, and fatigue may also occur with Ondansetron. Patients with preexisting hypertension have reported visual hallucinations as well as an increase in blood pressure. ECG changes have been observed with high-dose intravenous Tropisetron, including prolongation of the QT interval and ECG changes. Patients with irregular cardiac rhythms or conduction problems should not use the drug. Take care when operating machinery or driving. A reduction in dosage is not necessary for renal or liver impairment.
Tropisetron (5-HT3 antagonist) has an antiemetic activity similar to Ondansetron. It is used for nausea and vomiting prevention and post-operative nausea and vomiting. Tropisetron hydrochloride can be given intravenously or orally via slow intravenous or infusion. The doses are expressed in terms of tropisetron bas 5.64 mg tropisetron hydrochloride equals about 5 mg tropisetron bas